Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2025

S-Nitrosylated COX-2 is a TME-regulated breast cancer biomarker of mesenchymal phenotypes

View Full Paper
Ask AI
Bookmark
Share

Authors

RHReuben HoffmannABAeSoon BensenMDMark Dane

Discussion

Loading...

Member takes

Overview

Research demonstrates SNO-COX-2 expression correlates with mesenchymal traits in early-stage breast cancer, suggesting inflammation's role in tumor behavior.

Key Points

  • SNO-COX-2 expression is closely linked to mesenchymal phenotypes in MCF10DCIS cells.
  • Non-nitrosylated COX-2 does not show strong association with invasive tumor features in this model.
  • Increased SNO-COX-2 levels are influenced by specific tumor microenvironment conditions.
  • SNO-COX-2 shows potential utility as a biomarker for assessing breast cancer progression risk.

Cite This Study

Hoffmann et al. (2025) studied this question.

synapsesocial.com/papers/689a0c7be6551bb0af8d0765https://doi.org/10.1101/2025.07.15.664474
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1COX-2 Mediates Immune Evasion and Decreases Chemosensitivity in Breast Cancer Through Activation of the JAK2/STAT3 Signalling Pathway.2025
  2. 2Expression of cyclooxygenase-2 and smooth muscle actin biomarkers in different subtypes of basal cell carcinoma2025
  3. 3<em>In Vitro</em> and <em>In Vivo</em> Characterization of ENOX2 (tNOX) Stemness Properties in Oral Cancer2025
  4. 4Distinct Oxidative Stress Adaptations Driven by the Overexpression of miR-526b, miR-655, and COX-2 in Breast Cancer2025
  5. 5053. SIGNIFICANCE OF COX2 INHIBITOR FOR ESOPHAGEAL CANCER FROM THE CLINICAL AND EXPERIMENTAL ESTIMATE2025